Jahan Marcu, Ph.D.

Dr. Jahan Marcu
Jahan Marcu, Ph.D., Chief Scientific Officer and Chief Auditor for Americans for Safe Access and the Patient Focused Certification Program, serves on the board of various trade and science organization committees, including the American Chemical Society, the International Association for Cannabinoid Medicines, and the American Herbal Products Association. Marcu received his Ph.D. from Temple University for his study of the structure and function of the CB1 receptor and the role of the endocannabinoid system in bone. Before earning his Ph.D., Marcu worked at the California Pacific Medical Center Research Institute studying the anti-cancer properties of cannabis compounds, which formed the basis of an article in the Journal of Molecular Cancer Therapeutics. He is also a co-author of the American Herbal Pharmacopoeia’s Cannabis Monograph. Dr. Marcu is a court-qualified synthetic cannabinoid and cannabis expert. 

Cannabis & Cancer

Cannabis and cancer studies
Millions of Americans now have access to medical marijuana. When it comes to cancer treatment, beyond helping with the nausea of chemotherapy, there is strong scientific evidence of a deeper benefit of using cannabis with conventional therapies.

CBD and Epilepsy

CBD for epilepsy

Cannabis and its derivatives have been documented for anti-epileptic effects since 1881. Today, the promise of cannabidiol (CBD) as an anti-epileptic treatment is prompting people to move to states that have safe access to medicinal products containing this compound.